One form of cancer that begins in the thyroid gland, which produces hormones that assist in controlling metabolism, heart rate, blood pressure, and body temperature, is thyroid cancer. Papillary thyroid carcinoma is the most prevalent kind of thyroid cancer and is thought to have the greatest overall "prognosis" when properly treated.
Similar to thyroid cancer, follicular thyroid cancer responds well to therapy. Because they originate from cells that produce thyroid hormones, which are crucial for controlling metabolism, they are collectively referred to as "thyroid epithelial" malignancies.
Because the cancer cells act like normal thyroid tissue, consuming iodine and producing thyroid hormones, both tumors are referred to as "Differentiated Thyroid Cancer". More than 90% of thyroid tumors are differentiated thyroid cancers (DTC) of the thyroid epithelium. About 85% of DTC are papillary, 10% are follicular, and 3% are Hurthle cell carcinomas as a result of inadequate iodine feeding.
A Comprehensive Market Analysis:
DataM Intelligence reports can help you make the right business decisions. It is an analysis of the market and industry, which helps in understanding the market better. This report will provide you with all the information you need to know about this sector so that it becomes easy for you to make informed decisions.
Our market research reports offer a comprehensive overview of this sector and its dynamics. We have done extensive research on this topic and are confident that our findings will be helpful for anyone who needs some guidance or direction when making important decisions related to their company’s future growth strategy.
Market Size and Growth Rate:
The Global Differentiated Thyroid Cancer Drugs Market is expected to grow at a high CAGR during the forecasting period (2023-2030). The rising prevalence of thyroid cancer is one of the main causes driving the worldwide market growth for differentiated thyroid cancer drugs.
Differentiated Thyroid Cancer Drugs Market Dynamics:
- Differentiated thyroid cancer is often treated with radioactive iodine therapy, chemotherapy, and external beam radiation therapy. These therapies are only used when cancer has spread to other parts of the body or has proven resistant to prior therapies.
- For instance, a phase 3 study of donafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, is being conducted by Suzhou Zelgen Biopharmaceuticals Co., Ltd. and is anticipated to be finished in 2021. The study will evaluate efficacy and safety in patients with 131I-refractory/resistant differentiated thyroid cancer.
- The follicular thyroid cancer drug industry is being hampered by the product recall of a few medications. Because they were made with active pharmaceutical ingredients obtained prior to the FDA's Import Alert of Sichuan Friendly Pharmaceutical Co., Ltd., Westminster Pharmaceuticals voluntarily recalled Levothyroxine and Liothyronine tablets in August 2018 as a precaution.
Market Key Players:
The global differentiated thyroid cancer drugs market is quite competitive with some key competitors like
- Mylan Pharmaceuticals Inc.
- Baxter International Inc.
- Alara Pharmaceutical Corporation
To better understand the global differentiated thyroid cancer drugs market, its opportunities, and challenges, we invite you to request a sample report from DataM Intelligence. This comprehensive report will provide valuable insights into the market dynamics, helping business decision-makers, investors, CXOs, and R&D professionals make informed decisions in this rapidly evolving industry.
To Know More Download Sample
